๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial

โœ Scribed by Y. Lecrubier; P. Quintin; M. Bouhassira; E. Perrin; S. Lancrenon

Book ID
109341201
Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
186 KB
Volume
114
Category
Article
ISSN
0001-690X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Efficacy of selegiline add on therapy to
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study
โœ Afshar Amiri; Ahmad-Ali Noorbala; Ali-Akbar Nejatisafa; Abolfazl Ghoreishi; Moha ๐Ÿ“‚ Article ๐Ÿ“… 2008 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 100 KB

## Abstract ## Objective It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOIโ€B), at low doses would be helpful for treating negative symptoms in schizophrenia. Nevertheless, the results are contradictory so far. This study was designed to investigate the effect of

Mirtazapine add-on therapy in the treatm
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial
โœ Michael Berk; Clarissa S. Gama; Suresh Sundram; Harry Hustig; Les Koopowitz; Rus ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 1 views

## Abstract ## Objective Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, parti

A 6-month, randomized, double-blind, pla
A 6-month, randomized, double-blind, placebo-controlled pilot discontinuation trial following response to haloperidol treatment of psychosis and agitation in Alzheimer's disease
โœ D.P. Devanand; Gregory H. Pelton; Karine Cunqueiro; Harold A. Sackeim; Karen Mar ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 215 KB ๐Ÿ‘ 2 views

## Abstract ## Objective In patients with Alzheimer's disease (AD) with psychosis or agitation that respond to haloperidol treatment, to evaluate the risk of relapse following discontinuation. ## Methods In outpatients with AD with symptoms of psychosis or agitation, responders to 20 weeks of ha